Live Feed

Phillips 66 Limited today announced it has completed the acquisition of the assets and associated infrastructure of Prax Lindsey Oil Refinery Limited (in Liquidation). The transaction comes after the company previously agreed to the deal in January, stating its intention to integrate key assets into its Humber Refinery operations. "Completing this transaction allows Phillips 66 to play an even stronger role in supporting the UK's fuel supply and the resilience of this critical energy infrastructure," said Paul Fursey, Phillips 66 Limited UK lead executive. "This strategic move will unlock new growth opportunities for traditional and renewable fuels and help protect UK energy security at a

ST. LOUIS, April 27, 2026 /PRNewswire/ -- Energizer Holdings, Inc. (NYSE:ENR) announced that its Board of Directors declared a dividend on its common stock of $0.30 per share. The dividend will be payable on June 10, 2026, to shareholders of record as of the close of business on May 20, 2026. About Energizer Holdings, Inc.Energizer Holdings, Inc. ((", Energizer", , NYSE:ENR), headquartered in St. Louis, Missouri, is one of the world's largest manufacturers and distributors of primary batteries, portable lights, and auto care appearance, performance, refrigerant, and fragrance pr

SCHEDULE 13D/A - Motorsport Games Inc. (0001821175) (Subject)

MEXICO CITY, April 27, 2026 (GLOBE NEWSWIRE) -- Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (NYSE:VLRS, BMV:VOLAR) ("Volaris" or "the Company"), the ultra-low-cost carrier (ULCC) serving Mexico, the United States, Central and South America, today reports its unaudited financial results for the first quarter 20261. Enrique Beltranena, President & Chief Executive Officer, said: "Our first-quarter results reflect disciplined execution, as we strengthened revenue quality, optimized capacity deployment, and maintained cost control in a more challenging fuel environment. Demand remained solid across our network, supported by continued momentum in cross-border markets and strong top-

SCHEDULE 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)

SCHEDULE 13G/A - StepStone Group Inc. (0001796022) (Subject)

SCHEDULE 13D/A - Insight Molecular Diagnostics Inc. (0001642380) (Subject)

SÃO PAULO, April 27, 2026 /PRNewswire/ -- 1Q26 HighlightsAdjusted EBITDA (earnings before interest, taxes, depreciation and amortization) of R$3.0 billion in 1Q26, up 25% from 4Q25. Notably, North America accounted for 75% of the Company's Consolidated EBITDA in the first quarter of 2026.Investments (CAPEX) of R$1.1 billion in 1Q26, 27% lower than in 4Q25, in line with guidance of R$4.7 billion for 2026.Return to shareholders: the Company approved a dividend distribution of R$0.18 per share, equivalent to R$354.1 million, to be paid as of June 09, 2026. Also, advanced with the 2026 Share Buyback Program, with the acquisition of 21% of the authorized shares in Gerdau S.A.Inauguration of the B

RANCHO CORDOVA, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Five Star Bancorp (NASDAQ:FSBC) ("Five Star" or the "Company"), a holding company that operates through its wholly owned banking subsidiary, Five Star Bank (the "Bank"), today reported net income of $18.6 million for the three months ended March 31, 2026, as compared to $17.6 million for the three months ended December 31, 2025 and $13.1 million for the three months ended March 31, 2025. First Quarter Highlights Performance and operating highlights for the Company for the periods noted below included the following:  Three months ended(in thousands, except per share and share data)March 31,2026 December 31,2025 March 31,2025Return

Sally Beauty Holdings, Inc. (NYSE:SBH) (the "Company"), the leader in professional hair color, announced today that it will host a conference call and webcast on May 11, 2026, at 7:30 a.m. Central Time, to discuss its second quarter financial results. A copy of the press release announcing the second quarter financial results is expected to be made available on May 11, 2026, before the U.S. financial markets open on the Company's website sallybeautyholdings.com/investor-relations. During the conference call, the Company may discuss and answer one or more questions concerning business and financial matters and trends affecting the Company. The Company's responses to these questions, as wel

144 - Grayscale Avalanche Staking ETF (0002035053) (Subject)

SCHEDULE 13D/A - BlackRock ESG Capital Allocation Term Trust (0001864843) (Subject)

PANAMA CITY, April 27, 2026 /PRNewswire/ -- Bladex (NYSE:BLX, or ", the Bank", )), a Panama-based multinational bank originally established by the central banks of 23 Latin-American and Caribbean countries to promote foreign trade and economic integration in the Region, announced today its results for the First Quarter ("1Q26") ended March 31, 2026. The consolidated financial information in this document has been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB").  Financial & Business HighlightsSolid profitability with Net Profits reaching $56.4 million in 1Q26 (+9% YoY), supported by continued

PANAMA CITY, April 27, 2026 /PRNewswire/ -- Bladex announced today its Board of Directors' approval of a quarterly cash dividend of US$0.6875 per share corresponding to the first quarter of 2026. The cash dividend is payable May 27, 2026 to the Bank's stockholders as of May 8, 2026 record date.As of March 31, 2026, Bladex had 37,536,498.88 shares outstanding of all classes.Bladex, a multinational bank originally established by the central banks of Latin-American and Caribbean countries, began operations in 1979 to promote foreign trade and economic integration in the Region.  The Bank, headquartered in Panama, also has offices in Argentina, Brazil, Colombia, Mexico, the United States of Amer

MINNEAPOLIS, April 28, 2026 /PRNewswire/ -- Polaris Inc. (NYSE:PII) reported first quarter 2026 financial results today through an earnings release posted on the Company's Investor Relations website at ir.polaris.com.  The earnings release will be furnished with the Securities and Exchange Commission on a Form 8-K and is available at sec.gov.  The Company will also hold a conference call with analysts and investors today at 9:00 a.m. CT. Conference Call and Webcast DetailsThe call and webcast can be accessed via the Webcast link on our website at ir.polaris.com or by dialing 1-8

144 - BlackRock, Inc. (0002012383) (Subject)

Revenues of $2.05 billionNet income of $19 million, or $0.05 per shareAdjusted EBITDA* of $177 millionBookings of $520 million, representing a book-to-bill of 80%Returned $100 million of capital to shareholders through share repurchases and dividends *Free Cash Flow, Excess Free Cash Flow, Adjusted Operating Profit, and Adjusted EBITDA are non-GAAP measures, see "Non-GAAP Financial Measures," and "Reconciliation of GAAP to non-GAAP measures" below. HOUSTON, April 27, 2026 (GLOBE NEWSWIRE) -- NOV Inc. (NYSE:NOV) today reported first quarter 2026 revenues of $2.05 billion, a decrease of two percent compared to the first quarter of 2025. Net income decreased $54 million, or $0.14 per dilu

Turning Point Brands, Inc. (NYSE:TPB) announced the date and time for its conference call to review first quarter 2026 results. The conference call will be on Thursday, May 7, 2026 at 8:30 a.m. Eastern Time. Interested analysts and professional investors can register and participate through one of these call-in numbers: (800) 715-9871 (U.S., toll-free) (646) 307-1963 (International) Event ID: 4128483 Participants should dial in at least ten minutes in advance and follow the audio prompts after typing in the Event ID. The call will also be broadcast live as a listen-only webcast from the investor relations section of the company's website at http://www.turningpointbrands.com/investor-r

A 52% increase from baseline in mean C-peptide AUC at Week 12 in patients diagnosed within 0–3 years (n=5) receiving icovamenib 200 mg, with a clear dose response observed vs 100 mg (n=6)Persistence observed through Week 52, with mean C-peptide AUC largely preserved in 200 mg group (~7% decline from baseline) following only 12 weeks of dosingPreservation of C-peptide also observed in patients diagnosed between 3-15 years (n=9)Icovamenib was generally well tolerated across all dosing arms and demonstrated a favorable safety and tolerability profile through Week 52 Comprehensive dataset to be presented at the American Diabetes Association's (ADA) Scientific Sessions (abstract is preliminary un

DEF 14A - Revolution Medicines, Inc. (0001628171) (Filer)